Literature DB >> 32988968

Enhanced Detection of Treatment Effects on Metastatic Colorectal Cancer with Volumetric CT Measurements for Tumor Burden Growth Rate Evaluation.

Michael L Maitland1,2, Julia Wilkerson3, Sanja Karovic4, Binsheng Zhao5, Jessica Flynn6, Mengxi Zhou3, Patrick Hilden6, Firas S Ahmed5, Laurent Dercle5, Chaya S Moskowitz6, Ying Tang7, Dana E Connors8, Stacey J Adam8, Gary Kelloff8, Mithat Gonen6, Tito Fojo3, Lawrence H Schwartz5, Geoffrey R Oxnard9.   

Abstract

PURPOSE: Mathematical models combined with new imaging technologies could improve clinical oncology studies. To improve detection of therapeutic effect in patients with cancer, we assessed volumetric measurement of target lesions to estimate the rates of exponential tumor growth and regression as treatment is administered. EXPERIMENTAL
DESIGN: Two completed phase III trials were studied (988 patients) of aflibercept or panitumumab added to standard chemotherapy for advanced colorectal cancer. Retrospectively, radiologists performed semiautomated measurements of all metastatic lesions on CT images. Using exponential growth modeling, tumor regression (d) and growth (g) rates were estimated for each patient's unidimensional and volumetric measurements.
RESULTS: Exponential growth modeling of volumetric measurements detected different empiric mechanisms of effect for each drug: panitumumab marginally augmented the decay rate [tumor half-life; d [IQR]: 36.5 days (56.3, 29.0)] of chemotherapy [d: 44.5 days (67.2, 32.1), two-sided Wilcoxon P = 0.016], whereas aflibercept more significantly slowed the growth rate [doubling time; g = 300.8 days (154.0, 572.3)] compared with chemotherapy alone [g = 155.9 days (82.2, 347.0), P ≤ 0.0001]. An association of g with overall survival (OS) was observed. Simulating clinical trials using volumetric or unidimensional tumor measurements, fewer patients were required to detect a treatment effect using a volumetric measurement-based strategy (32-60 patients) than for unidimensional measurement-based strategies (124-184 patients).
CONCLUSIONS: Combined tumor volume measurement and estimation of tumor regression and growth rate has potential to enhance assessment of treatment effects in clinical studies of colorectal cancer that would not be achieved with conventional, RECIST-based unidimensional measurements. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2020        PMID: 32988968      PMCID: PMC8170504          DOI: 10.1158/1078-0432.CCR-20-1493

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  48 in total

Review 1.  Other paradigms: growth rate constants and tumor burden determined using computed tomography data correlate strongly with the overall survival of patients with renal cell carcinoma.

Authors:  Wilfred D Stein; Hui Huang; Michael Menefee; Maureen Edgerly; Herb Kotz; Andrew Dwyer; James Yang; Susan E Bates
Journal:  Cancer J       Date:  2009 Sep-Oct       Impact factor: 3.360

2.  Evaluating Continuous Tumor Measurement-Based Metrics as Phase II Endpoints for Predicting Overall Survival.

Authors:  Ming-Wen An; Xinxin Dong; Jeffrey Meyers; Yu Han; Axel Grothey; Jan Bogaerts; Daniel J Sargent; Sumithra J Mandrekar
Journal:  J Natl Cancer Inst       Date:  2015-08-21       Impact factor: 13.506

3.  Measurement of tumor volumes improves RECIST-based response assessments in advanced lung cancer.

Authors:  P David Mozley; Claus Bendtsen; Binsheng Zhao; Lawrence H Schwartz; Matthias Thorn; Yuanxin Rong; Luduan Zhang; Andrea Perrone; René Korn; Andrew J Buckler
Journal:  Transl Oncol       Date:  2012-02-01       Impact factor: 4.243

4.  Distinct Phenotypic Clusters of Glioblastoma Growth and Response Kinetics Predict Survival.

Authors:  Corbin A Rayfield; Fillan Grady; Gustavo De Leon; Russell Rockne; Eduardo Carrasco; Pamela Jackson; Mayur Vora; Sandra K Johnston; Andrea Hawkins-Daarud; Kamala R Clark-Swanson; Scott Whitmire; Mauricio E Gamez; Alyx Porter; Leland Hu; Luis Gonzalez-Cuyar; Bernard Bendok; Sujay Vora; Kristin R Swanson
Journal:  JCO Clin Cancer Inform       Date:  2018-12

5.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

Authors:  E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij
Journal:  Eur J Cancer       Date:  2009-01       Impact factor: 9.162

6.  RECIST: no longer the sharpest tool in the oncology clinical trials toolbox---point.

Authors:  Manish R Sharma; Michael L Maitland; Mark J Ratain
Journal:  Cancer Res       Date:  2012-09-04       Impact factor: 12.701

7.  Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials.

Authors:  Charles Ferté; Marianna Fernandez; Antoine Hollebecque; Serge Koscielny; Antonin Levy; Christophe Massard; Rastislav Balheda; Brian Bot; Carlos Gomez-Roca; Clarisse Dromain; Samy Ammari; Jean-Charles Soria
Journal:  Clin Cancer Res       Date:  2013-11-15       Impact factor: 12.531

8.  Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab-Treated Advanced Melanoma.

Authors:  M S Chatterjee; J Elassaiss-Schaap; A Lindauer; D C Turner; A Sostelly; T Freshwater; K Mayawala; M Ahamadi; J A Stone; R de Greef; A G Kondic; D P de Alwis
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2016-11-29

9.  Exposure-Response Analysis of Necitumumab Efficacy in Squamous Non-Small Cell Lung Cancer Patients.

Authors:  E Chigutsa; A J Long; J E Wallin
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2017-07-13

10.  A Response Assessment Platform for Development and Validation of Imaging Biomarkers in Oncology.

Authors:  Hao Yang; Lawrence H Schwartz; Binsheng Zhao
Journal:  Tomography       Date:  2016-12
View more
  2 in total

1.  Tumour growth rate improves tumour assessment and first-line systemic treatment decision-making for immunotherapy in patients with liver metastatic uveal melanoma.

Authors:  Toulsie Ramtohul; Axel Cohen; Manuel Rodrigues; Sophie Piperno-Neumann; Luc Cabel; Nathalie Cassoux; Livia Lumbroso-Le Rouic; Denis Malaise; Sophie Gardrat; Gaëlle Pierron; Pascale Mariani; Vincent Servois
Journal:  Br J Cancer       Date:  2022-03-26       Impact factor: 9.075

2.  Prediction of overall survival in patients across solid tumors following atezolizumab treatments: A tumor growth inhibition-overall survival modeling framework.

Authors:  Phyllis Chan; Mathilde Marchand; Kenta Yoshida; Shweta Vadhavkar; Nina Wang; Alyse Lin; Benjamin Wu; Marcus Ballinger; Nitzan Sternheim; Jin Y Jin; René Bruno
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-08-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.